We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · November 18, 2021

TOP1 Modulation During Melanoma Progression and in Adaptive Resistance to BRAF and MEK Inhibitors

Pharmacological Research

 

Additional Info

Pharmacological Research
TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors
Pharmacol Res 2021 Nov 01;173(xx)105911, ÉA Oliveira, J Chauhan, JRD Silva, LADC Carvalho, D Dias, DG Carvalho, LRM Watanabe, VW Rebecca, G Mills, Y Lu, ASF da Silva, MEL Consolaro, M Herlyn, PA Possik, CR Goding, SS Maria-Engler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading